ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: infliximab

New Guideline Recommends Frequent Monitoring & Collaboration for JIA-Associated Uveitis Management

Kelly Tyrrell  |  May 8, 2019

As soon as pediatric patients are diagnosed with juvenile idiopathic arthritis (JIA), they should also be screened for uveitis, says ophthalmologist Gary Holland, MD. Otherwise, the University of California, Los Angeles, provider says, “Kids who are diagnosed with JIA may not come to an ophthalmologist until they have vision-limiting complications.” Uveitis is the most common…

Filed under:Clinical Criteria/GuidelinesConditionsOther Rheumatic Conditions Tagged with:JIA-associated uveitis guidelinejuvenile idiopathic arthritis (JIA)Uveitis

kenary820 / shutterstock.com

Rheumatology Drugs at a Glance, Part 1: Psoriatic Arthritis

Mary Choy, PharmD, BCGP, FASHP  |  April 15, 2019

Over the past few years, biosimilars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, Rheumatology Drugs at a Glance, provides streamlined information on the administration of biologic, biosimilar and other medications used to…

Filed under:ConditionsDrug UpdatesPsoriatic Arthritis Tagged with:abataceptadalimumabapremilastbrodalumabCertolizumab PegoletanerceptGolimumabinfliximabixekizumabPsoriatic ArthritisRheumatic Drugs at a GlancesecukinumabTofacitinibtreatment guidelinesustekinumab

Metrics in Rheumatology: Focus on Harold E. (Hal) Paulus, MD

Gretchen Henkel  |  April 11, 2019

We have just learned that Dr. Hal Paulus passed away on April 5, 2019. We are reposting this story today in his memory and will share additional information as we learn it.

Filed under:ConditionsProfilesResearch Rheum Tagged with:CareerPatientsPaulusResearchTraining

Biosimilars: How Do They Affect Patient Care & Safety?

Lara C. Pullen, PhD  |  March 19, 2019

CHICAGO—“We have got to get over this hump. We have got to try new stuff,” said Jacqueline M. Fritz, RN, MSN, CNS, to the audience gathered on the final day of the 2018 ACR/ARHP Annual Meeting, referring to the subject of biosimilars. Ms. Fritz, the owner and coordinator of education at the Medical Advancement Center…

Filed under:Biologics/DMARDsDrug UpdatesMeeting Reports Tagged with:2018 ACR/ARHP Annual Meetingadalimumab-attoetanercept-szzsfilgrastim-sndzinfliximab-abdainfliximab-dyyb

Duration & Treatment of Musculoskeletal Symptoms of Immunotherapy-Induced Arthritis

Arthritis Care & Research  |  March 4, 2019

A new case series outlines the treatment and duration of symptoms of 10 patients experiencing the musculoskeletal manifestations of immune-related adverse events. Researchers found these symptoms may last for more than a year, but can generally be treated with low to moderate doses of corticosteroids…

Filed under:ConditionsResearch Rheum Tagged with:adverse eventsArthritis Care & Researchimmune-related adverse eventsimmunotherapyimmunotherapy-induced arthritis

Coding Corner Question: A Quiz on Modifiers

From the College  |  February 18, 2019

Which modifier is used when there is a separate and/or identifiable reason to bill for both an evaluation and management code and a procedure code? -25 -24 -51 -59 Which modifier is used to indicate that bilateral procedures were done on a patient? -50 -LT/RT Both a and b None of the above A 68–year-old…

Filed under:Billing/CodingFrom the College Tagged with:clinical modification codesModifier

WindNight / shutterstock.com

Why & How Our Biologic Drug Discussion with Patients Should Evolve

Paul H. Caldron, DO, PhD, MBA, & John R.P. Tesser, MD  |  February 17, 2019

As we turn the corner on the second decade of biologic use for rheumatic disorders, a reappraisal of approach in our communication with patients is due. In practice, the impact these agents have on patients’ lives justifies the friction rheumatologists face when connecting patients to them. You can understand why older rheumatologists who apprenticed on…

Filed under:Biologics/DMARDsResearch RheumRheumatoid ArthritisSpeak Out Rheum Tagged with:OpinionSpeak Out Rheumatology

Coding Corner Answers: Billing for Joint Injection within a Series

From the College  |  January 17, 2019

Take the challenge. CPT: 20611-LT, J7325-EJ ICD-10: M17.12, E66.01, Z68.41 Coding/Billing Rationale No evaluation and management (E/M) code was added because there was no significant and/or separate identifiable reason for an E/M service to be billed with this scheduled visit for her series of injections. The joint injection was billed with ultrasound guidance due to…

Filed under:Billing/CodingFrom the College Tagged with:Joint InjectionsKnee Osteoarthritis (OA)

Predicting the Unpredictable – Taming the Impulse to Treat

Philip Seo, MD, MHS  |  January 17, 2019

One of my fellows could take better care of his patients if it weren’t for the attendings getting in his way. Or so he tells me. I can hear the howls of protest already. This statement isn’t fair—it is too broad, it doesn’t fairly depict the nuances of the situation or his point of view. First,…

Filed under:ConditionsOpinionRheuminationsSpeak Out Rheum Tagged with:early arthritisVery Early Rheumatoid Arthritis

Can Integrated Care Lead to Better Outcomes?

Can Integrated Care Lead to Better Outcomes?

Shikha Mittoo, MD, MHS, FRCPC  |  December 17, 2018

A typical patient with a rheumatic disease needs a multifaceted treatment approach to address comorbidities, minimize disability, promote quality of life and improve survival. To achieve these outcomes, rheumatology research has evolved from examining a single treatment to studying the best treatment approaches. Examples of these strategy trials include how to best combine pharmaceutical therapies,…

Filed under:Conditions Tagged with:Association of Rheumatology Professionals (ARP)Integrated Careinterdisciplinarymultidisciplinary care

  • « Previous Page
  • 1
  • …
  • 14
  • 15
  • 16
  • 17
  • 18
  • …
  • 41
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences